Chronic Myeloid Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Novartis drug TasignaŽ (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children - GlobeNewswire (press release)



Novartis drug TasignaŽ (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children 
GlobeNewswire (press release)
Basel, November 20, 2017 - Novartis announced today that the European Commission (EC) approved TasignaŽ (nilotinib) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic ...
Novartis Secures EU Approval for Tasigna Treatment in Children Fox Business

all 3 news articles » 


Sprycel Approved for Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase - Managed Care magazine



Cancer Therapy Advisor
 
Sprycel Approved for Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase 
Managed Care magazine
The FDA has expanded the indication for dasatinib tablets (Sprycel, Bristol-Myers Squibb Company) to include the treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. Approval was based on data ...
Dasatinib Approved to Treat Chronic Myeloid Leukemia in Pediatric Patients Specialty Pharmacy Times
FDA Expands Approval Of Bristol-Myers Squibb Myeloid Leukemia Treatment Pharmaceutical Processing
FDA Approves Dasatinib for Pediatric Philadelphia Chromosome-positive CML Cancer Therapy Advisor
Oncology Nurse Advisor  -The Pharma Letter 
all 6 news articles » 


FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay ... - OncLive



OncLive
 
FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay ... 
OncLive
Gina Columbus reports on FDA approvals in chronic myeloid leukemia, cutaneous T-cell lymphoma, cytomegalovirus infection, and a tumor assay, and clinical ...

and more » 


U.S. Food and Drug Administration Expands Approval of Sprycel ... - Business Wire (press release)



Rare Disease Report
 


Devils' Brian Boyle set for season debut after cancer fight - USA TODAY



Bleacher Report
 
Devils' Brian Boyle set for season debut after cancer fight 
USA TODAY
"It's been a long road," the 32-year-old center said after the Devils' morning skate at Rogers Arena. "I'm excited." Boyle started to feel fatigued in August, and tests at the start of training camp revealed that he had chronic myelogenous leukemia, a ...
Devils' Brian Boyle 'thankful' to be able to play hockey NorthJersey.com
Brian Boyle to Make Devils Debut After Leukemia Diagnosis Bleacher Report
New Jersey Devils vs. Vancouver Canucks: RECAP, score, chat (11/1/17) NJ.com
New York Post  -Reuters  -CBS New York 
all 90 news articles » 


Responses Better With Bosutinib vs Imatinib in Untreated CML - Cancer Network



Responses Better With Bosutinib vs Imatinib in Untreated CML 
Cancer Network
Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the BFORE trial. Patients assigned bosutinib had a higher ...

 


Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival? - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival? 
Cancer Therapy Advisor
Left untreated, patients diagnosed with chronic myeloid leukemia (CML) in the chronic phase (CP) eventually progress to the accelerated (AP) or blast (BP) phase, a transition associated with multiple genetic changes. Although cytogenetic abnormalities ...

 


Radotinib for CML Yields Better Responses Than Imatinib - Cancer Network



Radotinib for CML Yields Better Responses Than Imatinib 
Cancer Network
Among patients with newly diagnosed, Philadelphia chromosome?positive chronic-phase chronic myeloid leukemia (CML), a lower-dose regimen of radotinib demonstrates superior complete cytogenetic response (CCyR) and major molecular response ...

 


A lot has happened in just one quarter of this NHL season - NHL.com



NHL.com
 
A lot has happened in just one quarter of this NHL season 
NHL.com
It was also his first game back from being treated for chronic myeloid leukemia. Boyle crashed the net hard and scored a type of goal he has many times before, but the celebration was a little different. He couldn't control the tears and said so himself.

 


Brian Boyle practices with Devils for 1st time since leukemia ... - NJ.com



NJ.com